117
Participants
Start Date
May 13, 2013
Primary Completion Date
January 10, 2014
Study Completion Date
March 1, 2014
PF-06291874
The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
Placebo
Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
MRA Clinical Research, LLC, South Miami
Profil Institute for Clinical Research, Inc., Chula Vista
Anaheim Clinical Trials, Anaheim
Lead Sponsor
Pfizer
INDUSTRY